Treatment with a beta-2-adrenoceptor agonist stimulates glucose uptake in skeletal muscle and improves glucose homeostasis, insulin resistance and hepatic steatosis in mice with diet-induced obesity

Anastasia Kalinovich, Nodi Dehvari, Alice Aslund, Sten van Beek, Carina Halleskog, Jessica Olsen, Elisabete Forsberg, Evelyn Zacharewicz, Gert Schaart, Mia Rinde, Anna Sandstrom, Roger Berlin, Claes-Goran Ostenson, Joris Hoeks, Tore Bengtsson*

*Corresponding author for this work

Research output: Contribution to journalArticleAcademicpeer-review

Original languageEnglish
Pages (from-to)1603-1615
Number of pages13
JournalDiabetologia
Volume63
Issue number8
DOIs
Publication statusPublished - Aug 2020

Keywords

  • beta(2)-Adrenergic signalling
  • Clenbuterol
  • Hepatic steatosis
  • Insulin resistance
  • Skeletal muscle
  • Type 2 diabetes
  • FATTY LIVER-DISEASE
  • WEIGHT-LOSS
  • CLENBUTEROL
  • SENSITIVITY
  • FORMOTEROL
  • ACCUMULATION
  • HYPOGLYCEMIA
  • INFLAMMATION
  • RECEPTORS
  • TOLERANCE

Cite this

Kalinovich, A., Dehvari, N., Aslund, A., van Beek, S., Halleskog, C., Olsen, J., Forsberg, E., Zacharewicz, E., Schaart, G., Rinde, M., Sandstrom, A., Berlin, R., Ostenson, C-G., Hoeks, J., & Bengtsson, T. (2020). Treatment with a beta-2-adrenoceptor agonist stimulates glucose uptake in skeletal muscle and improves glucose homeostasis, insulin resistance and hepatic steatosis in mice with diet-induced obesity. Diabetologia, 63(8), 1603-1615. https://doi.org/10.1007/s00125-020-05171-y